Group 1: Revenue Forecast - The company expects total revenue for the fiscal year 2025 to be approximately RMB 105 million to RMB 110 million, with core business revenue projected at RMB 90 million to RMB 92 million and other income estimated at RMB 15 million to RMB 18 million [1] Group 2: Business Development - The company has received unconditional approval from the U.S. FDA for its key registration clinical trial of the self-developed transcatheter tricuspid valve replacement system, LuX-Valve Plus, marking a significant breakthrough in its globalization strategy and laying the foundation for future commercialization in the U.S. market [3] Group 3: Shareholding Changes - Duckling Fund, L.P. and its affiliates increased their holdings by 160,000 H shares at an average price of HKD 7.9981 per share, totaling approximately HKD 1.2797 million, raising their ownership stake from 5.99% to 6.04% [2]
健世科技-B发布2025年度收入预告，股东增持及产品获FDA批准